Permanent correction of an inherited ectodermal dysplasia with recombinant EDA

Author:  ["Olivier Gaide","Pascal Schneider"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

X-linked hypohidrotic ectodermal dysplasia (XLHED; OMIM 305100) is a genetic disorder characterized by absence or deficient function of hair, teeth and sweat glands1. Affected children may experience life-threatening high fever resulting from reduced ability to sweat2. Mice with the Tabby phenotype share many symptoms with human XLHED patients because both phenotypes are caused by mutations of the syntenic ectodysplasin A gene (Eda) on the X chromosome3,4. Two main splice variants of Eda, encoding EDA1 and EDA2, engage the tumor necrosis factor (TNF) family receptors EDAR and XEDAR, respectively5. The EDA1 protein, acting through EDAR, is essential for proper formation of skin appendages; the functions of EDA2 and XEDAR are not known. EDA1 must be proteolytically processed to a soluble form to be active6,7,8,9. Here, we show that treatment of pregnant Tabby mice with a recombinant form of EDA1, engineered to cross the placental barrier, permanently rescues the Tabby phenotype in the offspring. Notably, sweat glands can also be induced by EDA1 after birth. This is the first example of a developmental genetic defect that can be permanently corrected by short-term treatment with a recombinant protein.

Cite this article

Gaide, O., Schneider, P. Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. Nat Med 9, 614–618 (2003). https://doi.org/10.1038/nm861

View full text

>> Full Text:   Permanent correction of an inherited ectodermal dysplasia with recombinant EDA

The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local i

Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors